Positive top-line data for Ablynx in rare blood disorder

Belgium’s Ablynx has provided top-line data from the Phase III HERCULES study into caplacizumab against acquired thrombotic thrombocytopenic purpura (aTTP).

Treatment with caplacizumab in addition to standard-of-care resulted in a statistically significant reduction in time to platelet count response, the primary endpoint of the study.

The trial also met the first two key secondary endpoints, and the company says the safety profile is consistent with its mechanism of action and the Phase II TITAN study results.

Ablynx says the data will support the registration process for caplacizumab, which the company owns outright, in Europe and the USA.